Pharmaceutical Preparations: Clinical Trials

117 trials of Pharmaceutical Preparations, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed, 20 recruiting, 15 terminated, 15 unknown. 117 Phase 2, 23 Phase 1, 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2117Completed 46, Recruiting 20, Terminated 15, Unknown 15, Not yet recruiting 14, Active not recruiting 5, Suspended 1, Withdrawn 1
Phase 123Completed 8, Recruiting 6, Unknown 5, Not yet recruiting 4
Phase 312Completed 9, Not yet recruiting 1, Terminated 1, Unknown 1

Follow Pharmaceutical Preparations: new trials by email Literature Review of Pharmaceutical Preparations trials Research Report on Pharmaceutical Preparations

Trials (filtered) newest first · largest first

All 117 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Group PACBT for Depression
Psilocybin (drug), Group Cognitive Behavioral Therapy - Depression - Major Depressive Disorder, Psilocybin
Phase 2Not yet recruitingUniversity of California, Los Angeles302027-01-012026-05-04
Effects of Psilocybin on Craving in Nicotine Dependence
Psilocybin (drug) - Nicotine Dependence
Phase 2Not yet recruitingUniversity of British Columbia32027-01-012026-10-01
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder
Phase 2Not yet recruitingUniversity of New Mexico1502026-12-312026-10-30
Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia.
Spironolactone (drug), Iron Supplement, Erythropoietin stimulating agent - Anemia
Phase 2Not yet recruitingAin Shams University402026-12-012026-07-20
Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
Dapagliflozin (DAPA), Spironolactone (drug), Spironolactone + Dapagliflozin - Aortic Stenosis
Phase 2Not yet recruitingUniversity College, London4452026-12-012026-09-11
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
Psilocybin (drug), Standard of Care (SOC) - Psilocybin, Neuropathy
Phase 2SuspendedM.D. Anderson Cancer Center902026-11-042026-11-19
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
Lidocaine (drug), Saline - Refractory Migraine, Headache
Phase 2RecruitingDaniel A Tonetti, MD802026-09-092026-10-01
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
Phase 1 / Phase 2RecruitingVM Discovery, Inc.1112026-07-162026-11-03
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Psilocybin (drug) - Depression, Parkinson's Disease (PD)
Phase 2RecruitingYale University402026-07-102026-11-20
Efficacy and Mechanism of IPSRT for Bipolar II Disorder
Quetiapine (drug), Psychopharmacological treatment - Bipolar Disorder II
Phase 2Not yet recruitingFirst Affiliated Hospital of Zhejiang University2162026-07-012026-06-17
Letrozole Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
Methotrexate (drug), Letrozole 2.5Mg Tab - Ectopic Pregnancy
Phase 2Not yet recruitingKafrelsheikh University702026-06-012026-06-03
[18F]F-AraG PET Imaging in Alzheimer's Disease
Drug: [18F]F-AraG (PET tracer) - Alzheimer Disease (AD)
Phase 2Not yet recruitingCellSight Technologies, Inc.102026-05-162026-05-28
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
vicadrostat / empagliflozin combination 1, Spironolactone (drug) - CKD, Cardiovascular Diseases
Phase 2RecruitingUniversity Medical Center Groningen1002026-05-122026-05-29
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle., Spironolactone (drug) - Glioblastoma (GBM)
Phase 1 / Phase 2Not yet recruitingStarlight Therapeutics Inc.682026-05-012026-03-30
Combining Latency Reversing Agents to Address the HIV Reservoir
Pyrimethamine (PYR), Lenalidomide, Topiramate (drug) - HIV (Human Immunodeficiency Virus), HIV -1 Infection
Phase 1 / Phase 2Not yet recruitingErasmus Medical Center302026-04-012026-02-03
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
JPI-547, Irinotecan (drug) - Gastric Cancer (GC)
Phase 1 / Phase 2Not yet recruitingOnconic Therapeutics Inc.492026-02-272026-01-23
RCT of Psilocybin-assisted CBT for Depression
Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy - Major Depressive Diorder
Phase 1 / Phase 2RecruitingUniversity of California, Los Angeles502026-01-052026-02-12
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma
Phase 2 / Phase 3Not yet recruitingShanghai Zhongshan Hospital2222025-12-222025-12-30
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
Psilocybin (drug), Placebo - Treatment Resistant Depression
Phase 2RecruitingBeersheva Mental Health Center202025-12-012025-11-19
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety
Fluoxetine (drug), Placebo - Hepatobiliary Malignancy, Fluoxetine
Phase 2RecruitingFirst Affiliated Hospital of Wenzhou Medical University2402025-10-012026-03-24

Showing 20 of 117. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (5)  ·  HIV Infections (4)  ·  Neoplasms (4)  ·  Parkinson Disease (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Furcation Defects (3)  ·  Head and Neck Neoplasms (3)  ·  Lymphoma (3)  ·  Migraine Disorders (3)  ·  Anemia (2)  ·  Anxiety Disorders (2)  ·  Breast Neoplasms (2)  ·  Depression (2)  ·  Fibrosis (2)  ·  Headache (2)

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (6)  ·  University Health Network, Toronto (4)  ·  French National Agency for Research on AIDS and Viral Hepatitis (3)  ·  Government Dental College and Research Institute, Bangalore (3)  ·  University Hospital, Clermont-Ferrand (3)  ·  Yale University (3)  ·  ANRS, Emerging Infectious Diseases (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Bellus Health Inc. - a GSK company (2)  ·  International Extranodal Lymphoma Study Group (IELSG) (2)  ·  M.D. Anderson Cancer Center (2)  ·  Mayo Clinic (2)  ·  Sun Yat-sen University (2)  ·  University Hospital, Bordeaux (2)  ·  University of California, Los Angeles (2)

Countries

United States (33)  ·  France (15)  ·  Germany (15)  ·  Canada (12)  ·  China (8)  ·  Belgium (5)  ·  Netherlands (5)  ·  Australia (4)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  India (3)  ·  Poland (3)  ·  South Korea (3)  ·  Switzerland (3)

Top investigators

Genevieve Chene, MD, PhD (3)  ·  Salah-Eddin Al-Batran, Prof. (2)  ·  Salah-Eddin Al-Batran, Prof. Dr. (2)  ·  Stuart D Katz, MD (2)  ·  Susan H Fox, MRCP, PhD (2)  ·  Andre Cantin, md (1)  ·  Andrea C King, PhD (1)  ·  Barry J Byrne, MD, PhD (1)  ·  Bruno Scheller, MD (1)  ·  Caroline Altergott, MD (1)  ·  Caroline Sevin, MD, PhD (1)  ·  Casper Rokx, MD PhD (1)  ·  Cesar Serrano, MD (1)  ·  Channa Jayasekera (1)

Results publications

PMID 12064356, PMID 15060509, PMID 15456093, PMID 15583741, PMID 15784740, PMID 15890495, PMID 15978266, PMID 16002461, PMID 16194720, PMID 16495395, PMID 17101615, PMID 17119142, PMID 17434849, PMID 17554116, PMID 17591032, PMID 18425621, PMID 18461895, PMID 18536865, PMID 19958860, PMID 20025989, PMID 20819978, PMID 21704313, PMID 22440499, PMID 22585216, PMID 22794786, PMID 23177384, PMID 23190183, PMID 23570273, PMID 25552401, PMID 25568347, PMID 26243227, PMID 26451031, PMID 27712462, PMID 27751554, PMID 27758940, PMID 30800121, PMID 32026447, PMID 34182952, PMID 37821131, PMID 40520457, PMID 40803733, PMID 42254059

NIH funding

2004 (2), 2017 (1), 2025 (1), P01HL059412 (1), P30CA043703 (1), R01DA016834 (1), R01NS046309 (1), R34AT013077 (1), U10CA180886 (1)